Skip to content
Clinical Trials – home
NorwayBack to Norway

Clinical trials in Moss – page 10

130 clinical trials in Moss, Norway. Every trial is listed in the EU Clinical Trials Register and updated daily.

NorwayOur site in NorwayKliniske-Studier.no(opens in a new tab)
Moss at a glance
130
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

130 trials in Moss

Open in trial search

Study Comparing Camizestrant and Palbociclib with Anastrozole and Palbociclib for Patients with ER-Positive, HER2-Negative Advanced Breast Cancer Without Prior Treatment

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:AstraZeneca AB

Study of V940 and Pembrolizumab for Patients with Resected Stage II, IIIA, IIIB Non-Small Cell Lung Cancer

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:MRNA-4157
  • Sponsor:Merck Sharp & Dohme LLC

Study on the Safety and Effectiveness of Rilzabrutinib for Adults and Adolescents with Persistent or Chronic Immune Thrombocytopenia (ITP)

Investigational
Countries:NorwayNorway
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Rilzabrutinib
  • Sponsor:Principia Biopharma Inc.

Study of utreloxastat (PTC857) in adults with Amyotrophic Lateral Sclerosis (ALS) to evaluate its effectiveness in slowing disease progression

Investigational
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Utreloxastat
  • Sponsor:PTC Therapeutics Inc.

Study on Povetacicept for Patients with Autoimmune Cytopenias (wAIHA, CAD, ITP)

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Povetacicept
  • Sponsor:Alpine Immune Sciences Inc.

Rheumatoid arthritis

Not recruiting

Study on Monitoring Adalimumab for Maintaining Disease Control in Adults with Rheumatoid Arthritis

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years
  • Substances:Adalimumab
  • Sponsor:Diakonhjemmet Sykehus AS

Atrial fibrillation+2

Not recruiting

Study on Asundexian and Apixaban for Preventing Stroke in Adults with Atrial Fibrillation at Risk for Stroke

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Bayer AG

Multiple sclerosis

Not recruiting

Study on the Safety of Tenofovir Alafenamide and Natalizumab for People with Multiple Sclerosis

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years
  • Substances:Natalizumab
  • Sponsor:Helse Bergen HF

Study on the Effect of Adding Thoracic Radiotherapy to Durvalumab and Chemotherapy for Patients with Extensive Stage Small-Cell Lung Cancer

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Norwegian University Of Science And Technolology

Study Comparing SGN-B6A and Docetaxel for Adults with Previously Treated Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Seagen Inc.

Lung disorder

Not recruiting

Study on Baricitinib for Hospitalized Patients with Severe or Critical COVID-19

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Baricitinib
  • Sponsor:Oslo University Hospital HF

Lung disorder

Not recruiting

Study on the Effectiveness and Safety of Bemcentinib for Hospitalized Patients with Moderate COVID-19

Investigational
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Bemcentinib
  • Sponsor:Oslo University Hospital HF

Other cities in Norway

The busiest research cities in the country

All 53 cities in Norway

Clinical research in Moss

What the registry says about research in the country

01 Rheumatology & Immunology

Clinical research focusing on giant cell arteritis (GCA), exploring innovative therapeutic approaches for this rare inflammatory blood vessel condition. The trials aim to evaluate new treatment combinations that could improve patient outcomes while optimizing glucocorticoid therapy regimens.

  • Inflammatory Vascular Disorders
  • Autoimmune Disease Management
  • Targeted Immunotherapy

These investigations are designed to assess the effectiveness of combining novel biological treatments with traditional steroid therapies, potentially offering new hope for patients managing chronic inflammatory conditions.

02 Therapeutic Innovation

Advanced studies evaluating combination therapy approaches that integrate biological agents with standardized glucocorticoid tapering protocols. This research aims to establish more effective treatment strategies while potentially reducing long-term steroid exposure.

  • Treatment Optimization
  • Steroid-Sparing Strategies
  • Long-term Disease Management

The research focuses on developing sustained remission protocols that could revolutionize the standard of care for inflammatory vascular conditions.

03 Clinical Outcomes

Comprehensive evaluation of treatment efficacy and safety in vascular inflammation, with particular attention to sustained disease remission. The research examines both immediate therapeutic responses and long-term outcomes in patients with inflammatory arterial disease.

  • Remission Assessment
  • Safety Monitoring
  • Quality of Life Impacts

These trials are designed to provide crucial data on the effectiveness of new therapeutic approaches in achieving and maintaining disease control.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.